AstraZeneca Management

Management criteria checks 3/4

AstraZeneca's CEO is Pascal Soriot, appointed in Oct 2012, has a tenure of 11.5 years. total yearly compensation is $21.48M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 0.032% of the company’s shares, worth SEK828.36M. The average tenure of the management team and the board of directors is 10.3 years and 6.4 years respectively.

Key information

Pascal Soriot

Chief executive officer

US$21.5m

Total compensation

CEO salary percentage	8.5%
CEO tenure	11.5yrs
CEO ownership	0.03%
Management average tenure	10.3yrs
Board average tenure	6.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Pascal Soriot's remuneration changed compared to AstraZeneca's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$21m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$18m	US$2m	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$1b
Dec 31 2021	US$21m	US$2m	US$112m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$22m	US$2m	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$20m	US$2m	US$1b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$2m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$3b
Mar 31 2018	n/a	n/a	US$3b
Dec 31 2017	US$14m	US$2m	US$3b

Compensation vs Market: Pascal's total compensation ($USD21.48M) is above average for companies of similar size in the Swedish market ($USD3.21M).

Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.

CEO

Pascal Soriot (64 yo)

11.5yrs

Tenure

US$21,484,390

Compensation

Mr. Pascal Soriot, M.B.A., D.V.M., has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October 1, 2012. He served as Director at Acerta Pharma B.V. He had been Independent...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Pascal Soriot	CEO & Executive Director	11.5yrs	US$21.48m	0.032% $ 828.4m
Aradhana Sarin	CFO & Executive Director	2.7yrs	US$5.62m	0.0053% $ 137.0m
Pam Cheng	EVP of Global opt. & IT	8.8yrs	no data	no data
Andrew Barnett	Head of Investor Relations	no data	no data	no data
Jeffrey Pott	CHRO, Chief Compliance Officer	15.3yrs	no data	no data
Gonzalo Vina	Head of Global Media Relations	no data	no data	no data
Menelas Nicolas Pangalos	Executive Vice-President	11.3yrs	no data	no data
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	11.3yrs	no data	no data
Susan Galbraith	Executive Vice President of Oncology Research & Development	no data	no data	no data
Leon Wang	Executive VP of International & China President	10.3yrs	no data	no data
Iskra Reic	Executive Vice-President of Vaccines & Immune Therapies	7yrs	no data	no data
David Fredrickson	Executive Vice-President of Oncology Business Unit	6.5yrs	no data	no data

10.3yrs

Average Tenure

56yo

Average Age

Experienced Management: AZN's management team is seasoned and experienced (10.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Pascal Soriot	CEO & Executive Director	11.5yrs	US$21.48m	0.032% $ 828.4m
Aradhana Sarin	CFO & Executive Director	2.7yrs	US$5.62m	0.0053% $ 137.0m
Pam Cheng	EVP of Global opt. & IT	no data	no data	no data
Jeffrey Pott	CHRO, Chief Compliance Officer	no data	no data	no data
Marcus Wallenberg	Non-Executive Director	25yrs	US$159.35k	0.0039% $ 99.7m
Philip John Broadley	Senior Independent Non-Executive Director	7yrs	US$254.96k	0.00045% $ 11.6m
Michel Demare	Independent Chairman	4.6yrs	US$744.49k	0.00039% $ 10.0m
Deborah DiSanzo Eldracher	Independent Non-Executive Director	6.3yrs	US$152.98k	0.000060% $ 1.5m
Sherilyn S. McCoy	Independent Non-Executive Director	6.5yrs	US$223.09k	0.00011% $ 2.8m
Euan Ashley	Independent Non-Executive Director	3.5yrs	US$151.70k	0.000070% $ 1.8m
Shu Kam Mok	Independent Non-Executive Director	5.3yrs	US$140.23k	0.00013% $ 3.3m
Nazneen Rahman	Independent Non-Executive Director	6.8yrs	US$203.97k	0.000070% $ 1.8m

6.4yrs

Average Tenure

63yo

Average Age

Experienced Board: AZN's board of directors are considered experienced (6.4 years average tenure).

AstraZeneca Management

Management criteria checks 3/4

Key information

Recent management updates

AstraZeneca PLC, Annual General Meeting, Apr 11, 2024

AstraZeneca Announces Appointment of Manali Mukherjee as Chair in Respiratory Diseases

Recent updates

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

AstraZeneca PLC Reiterates Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$1.41 (vs US$1.16 in 1Q 2023)

Astrazeneca plc Announces IMFINZI (Durvalumab) Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial

AstraZeneca’s FASENRA Approves for Treatment of Children Aged 6 to 11 with Severe Asthma by the US Food and Drug Administration

AstraZeneca PLC Intends to Increase the Annualized Dividend for 2024

AstraZeneca PLC's Imfinzi Shows Significantly Improved Overall Survival and Progression-Free Survival for Patients with Limited-Stage Small Cell Lung Cancer in Adriatic Phase III Trial

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC Announces Ultomiris Approved in the US for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

AstraZeneca PLC (LSE:AZN) agreed to acquire Amolyt Pharma SAS for $1.05 billion.

AstraZeneca Announces Initiation of THARROS – Phase III Clinical Trial Investigating Potential of BREZTRI to Improve Cardiopulmonary Outcomes in People with COPD

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Astrazeneca plc Announces Voydeya Recommends for Approval in the Eu by Chmp as Add-On Treatment to Ravulizumab or Eculizumab

Full year 2023 earnings: EPS misses analyst expectations

AstraZeneca PLC, Annual General Meeting, Apr 11, 2024

Astrazeneca's Tagrisso®? (Osimertinib) Demonstrates Aggressive Efficacy Benefit for Patients with Unresectable, Stage Iii Efficacy-Mutated Lung Cancer in Laura Phase Iii Trial

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

AstraZeneca Announces TAGRISSO® (Osimertinib) with the Addition of Chemotherapy Approve in the US for Patients with EGFR-mutated advanced lung cancer

Upcoming dividend of kr20.65 per share at 2.4% yield

AstraZeneca Announces Appointment of Manali Mukherjee as Chair in Respiratory Diseases

Final dividend of kr20.65 announced

Full year 2023 earnings: EPS misses analyst expectations

AstraZeneca PLC to Report Q1, 2024 Results on Apr 25, 2024

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age